Molecular subtyping in urothelial carcinoma treatment
- PMID: 39658539
- DOI: 10.1016/j.ccell.2024.11.001
Molecular subtyping in urothelial carcinoma treatment
Abstract
The heterogeneity of urothelial carcinoma (UC) and variable treatment responses poses significant clinical challenges. In this issue of Cancer Cell, Hamidi et al. conducted a multi-omics analysis of 2,803 UC patients from four clinical trials with anti-PD-L1, revealing four transcriptional subtypes. This approach could help tailor therapies for UC.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests X.S. has the following potential conflicts of interest to disclose: non-profit consultant for Pfizer, Novartis, Astellas, AstraZeneca, Bayer, MSD, RemeGen, and Junshi Biosciences.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
